In this latest update, we look at recent developments in market access including the pricing agreement of Libmeldy® by the Beneluxa Initiative, the financial impact of managed entry agreements in Italy and the restructuring of Agenzia Italiana del Farmaco (AIFA). We also highlight the collaboration between FINOSE and the New Expensive Drug (NED) section of the Nordic Pharmaceutical Forum.
Keywords: AIFA; Agenzia Italiana del Farmaco; Beneluxa Initiative; EU HTA; FINOSE; NED; New Expensive Drug; health technology assessment; joint clinical assessment; managed entry agreements; market access.